Given Zydus Lifesciences and Dr Reddy’s Laboratories have high US sales exposure with ~45% and 43% sales contribution, ...

Jefferies pointed out that India currently imposes up to 10% import duties on US drugs, with some having lower duties or ...

Pharmaceutical company shares faced significant selling pressure, causing the Nifty Pharma index to decline by more than 2 ...

Citi's analysis indicates that companies with lower exposure to US generics, including Torrent Pharma, Sun Pharma, and Divi's ...

What sectors will be most impacted by Trump reciprocal tariffs that will go into effect on April 2: Donald Trump's Reciprocal ...

Mumbai: Abbott India has announced the appointment of Devesh Choudhari as Director - Finance effective April 1, 2025. He will ...

Goldman Sachs expects a sluggish trend to continue in the QSR business but expects recovery in the first half of financial ...

Despite the recent correction, the number of Rs1 lakh crore-plus market cap firms has slightly increased between the end of FY24 and early FY25. For perspective, FY23 and FY22 each recorded 48 ...

Zydus Lifesciences is a standout in terms of HR practices. From revision in pay to performance parameters, everything is ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain ...

Citi believes that Pharma companies will aim to pass on the tariff hikes to payors. In case the costs are not passed on to ...

Jefferies recommends six stocks for investment, focusing on sectors like power, ports, and cement due to strong private ...